ginkgolide b has been researched along with warfarin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kubota, Y; Shinozuka, K; Taki, Y; Umegaki, K; Watanabe, Y; Yamada, S; Yokotani, K | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
3 other study(ies) available for ginkgolide b and warfarin
| Article | Year |
|---|---|
Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice.
Topics: Animals; Anticoagulants; Blood Coagulation; Coagulants; Cyclopentanes; Cytochrome P-450 Enzyme System; Enzyme Induction; Furans; Ginkgo biloba; Ginkgolides; Herb-Drug Interactions; Lactones; Liver; Male; Mice; Mice, Inbred ICR; Plant Extracts; Warfarin | 2012 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |